Adjuvanted influenza vaccines

Expert Review of Vaccines

Volumn 12, Issue 9, 2013, Pages 1095-1108

  Even or, Orli ^a   Samira, Sarit ^b   Ellis, Ronald ^b   Kedar, Eli ^c   Barenholz, Yechezkel ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b NasVax Ltd   (Israel)

^c HEBREW UNIVERSITY   (Israel)

Author keywords

adjuvants; cationic liposomes; delivery systems; emulsions; immune responses; influenza vaccines; TLR; viral vectors; virosomes

Indexed keywords

DRUG CARRIER; IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE;

ANIMAL; DRUG DEVELOPMENT; HUMAN; IMMUNOLOGY; INFLUENZA, HUMAN; MEDICINAL CHEMISTRY; PROCEDURES; TRENDS;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CHEMISTRY, PHARMACEUTICAL; DRUG CARRIERS; DRUG DISCOVERY; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN;

EID: 84897355310     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.2013.825445     Document Type: Review

References (149)

1. Kuiken T, Riteau B, Fouchier RA, Rimmelzwaan GF. Pathogenesis of influenza virus infections: the good, the bad and the ugly. Curr. Opin. Virol. 2 (3), 276 – 86 (2012).
2. Hsieh YC, Wu TZ, Liu DP et al. Influenza pandemics: past, present and future. J. Formos. Med. Assoc. 105 (1), 1 – 6 (2006).
3. Cohen J. Swine flu outbreak. Past pandemics provide mixed clues to H1N1's next moves. Science 324 (5930), 996 – 997 (2009).
4. Sullivan SJ, Jacobson RM, Dowdle WR, Poland GA. 2009 H1N1 Influenza. Mayo. Clin. Proc. 85 (1), 64 – 76 (2010).
5. Centers for Disease Control and Prevention (CDC). Emergence of avian influenza A(H7N9) virus causing severe human illness–China, February–April 2013. MMWR 62 (18), 366 – 371 (2013).
6. Barry DW, Mayner RE, Staton E et al. Comparative trial of influenza vaccines: I. Immunogenicity of whole virus and split product vaccines in man. Am. J. Epidemiol. 104 (1), 34 – 46 (1976).
7. Couch RB. Seasonal inactivated influenza virus vaccines. Vaccine 26 (4), D 5 – 9 (2008).
8. Harper SA, Fukuda K, Uyeki TM, Cox NJ, Bridges CB. Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 54 (RR08), 1 – 40 (2005).
9. Beyer WE, Palache AM, Osterhaus AD. Comparison of serology and reactogenicity between influenza subunit vaccines and whole virus or split vaccines: a review and meta-analysis of the literature. Clin. Drug Invest. 15, 1 – 12 (1998).
10. Doroshenko A, Halperin SA. Trivalent MDCK cell culture-derived influenza vaccine Optaflu (Novartis Vaccines). Expert Rev. Vaccines 8 (6), 679 – 688 (2009).
11. Cox MM, Anderson DK. Production of a novel influenza vaccine using insect cells: protection against drifted strains. Influenza Other Respir. Viruses 1 (1), 35 – 40 (2007).
12. Treanor JJ, Schiff GM, Hayden FG, Brady RC, Hay CM, Meyer AL et al. Safety and immunogenicity of a baculovirus-expressed hemagglutinin influenza vaccine: a randomized controlled trial. JAMA 297 (14), 1577 – 1582 (2007).
13. Baxter R, Patriarca PA, Ensor K, Izikson R, Goldenthal KL, Cox MM. Evaluation of the safety, reactogenicity and immunogenicity of FluBlok® trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy adults 50-64 years of age. Vaccine 29 (12), 2272 – 2278 (2011).
14. Treanor JJ, Betts RF, Smith GE, et al. Evaluation of a recombinant hemagglutinin expressed in insect cells as an influenza vaccine in young and elderly adults. J. Infect. Dis. 173 (6), 1467 – 1470 (1996).
15. Treanor JJ, Sahly HE, King J et al. Protective efficacy of a trivalent recombinant hemagglutinin protein vaccine (FluBlok(®)) against influenza in healthy adults: A randomized, placebo-controlled trial. Vaccine 29 (44), 7733 – 7739 (2011).
16. King J C Jr, Cox MM, Reisinger K, Hedrick J, Graham I, Patriarca P. Evaluation of the safety, reactogenicity and immunogenicity of FluBlok trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy children aged 6-59 months. Vaccine 27 (47), 6589 – 6594 (2009).
17. Centers for Disease Control and Prevention (CDC). Licensure of a high-dose inactivated influenza vaccine for persons aged >or=65 years (Fluzone High-Dose) and guidance for use - United States. MMWR. 59 (16), 485 – 486 (2010).
18. Atmar RL, Patel SM, Keitel WA. Intanza: a new intradermal vaccine for seasonal influenza. Expert Rev. Vaccines 9 (12), 1399 – 1409 (2010).
19. Eizenberg P, Booy R, Naser N, Mason G, Stamboulian D, Weber F Acceptance of Intanza® 9 μg intradermal influenza vaccine in routine clinical practice in Australia and Argentina. Adv. Ther. 28 (8), 640 – 649 (2011).
20. Belshe RB, Mendelman PM, Treanor J et al. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine in children. N. Engl. J. Med. 338 (20), 1405 – 1412 (1998).
21. Boyce TG, Poland GA. Promises and challenges of live-attenuated intranasal influenza vaccines across the age spectrum: a review. Biomed. Pharmacother. 54 (4), 210 – 218 (2000).
22. Osterholm MT, Kelley NS, Sommer A, Belongia EA. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infect. Dis. 12 (1), 36 – 44 (2012).
23. De Villiers PJT, Steeleb AD, Hiemstrac LA et al. Efficacy and safety of a live attenuated influenza vaccine in adults 60 years of age and older. Vaccine 28 (1), 228 – 234 (2010).
24. Sever JL. Application of a microtechnique to viral serological investigations. J. Immunol. 88, 320 – 329 (1962).
25. Kelly HA, Sullivan SG, Grant KA, Fielding JE. Moderate influenza vaccine effectiveness with variable effectiveness by match between circulating and vaccine strains in Australian adults aged 20–64 years, 2007–2011. Influenza Other Respir. Viruses (2012) (Epub ahead of print).
26. Weinberger B, Grubeck-Loebenstein B. New technologies for new influenza vaccines. Vaccine 30 (33), 4927 – 4933 (2012).
27. Weinberger B, Grubeck-Loebenstein B. Vaccines for the elderly. Clin. Microbiol. Infect. 18 (Suppl. 5), 100 – 108 (2012).
28. Manzoli L, Ioannidis JP, Flacco ME, De Vito C, Villari P. Effectiveness and harms of seasonal and pandemic influenza vaccines in children, adults and elderly: A critical review and re-analysis of 15 meta-analyses. Hum. Vaccin. Immunother. 8 (7), 851 – 862 (2012).
29. Kelvin DJ, Farooqui A. Extremely low vaccine effectiveness against influenza H3N2 in the elderly during the 2012/2013 flu season. J. Infect. Dev. Ctries 7 (3), 299 – 301 (2013).
30. Treanor JJ, Talbot HK, Ohmit SE et al. Effectiveness of seasonal influenza vaccines in the United States during a season with circulation of all three vaccine strains. Clin. Infect. Dis. 55 (7), 951 – 959 (2012).
31. Siriwardena AN, Gwini SM, Coupland CA. Influenza vaccination, pneumococcal vaccination and risk of acute myocardial infarction: matched case-control study. CMAJ. 182 (15), 1617 – 1623 (2010).
32. Gwini SM, Coupland CA, Siriwardena AN. The effect of influenza vaccination on risk of acute myocardial infarction: self-controlled case-series study. Vaccine 29 (6), 1145 – 1149 (2011).
33. Jefferson T, Rivetti A, Di Pietrantonj C, Demicheli V, Ferroni E. Vaccines for preventing influenza in healthy children. Cochrane Database Syst. Rev. 8, CD004879 (2012).
34. Kissling E, Valenciano M, Larrauri A et al. Low and decreasing vaccine effectiveness against influenza A(H3) in 2011/12 among vaccination target groups in Europe: results from the I-MOVE multicenter case-control study. Euro. Surveill. 18 (5) (2013).
35. Schijns VE, Lavelle EC. Trends in vaccine adjuvants. Expert Rev. Vaccines 10 (4), 539 – 550 (2011).
36. Shoenfeld Y, Agmon-Levin N. ‘ASIA’–autoimmune/inflammatory syndrome induced by adjuvants. J. Autoimmun. 36 (1), 4 – 8 (2011).
37. Wang W, Singh M. Selection of adjuvants for enhanced vaccine potency. World J. Vaccines 1, 33 – 78 (2011).
38. Broderson JR. A retrospective review of lesions associated with the use of Freund's adjuvant. Lab. Anim. Sci. 39 (5), 400 – 405 (1989).
39. Jackson LR, Fox JG. Institutional Policies and Guidelines on Adjuvants and Antibody Production. ILAR J. 37 (3), 141 – 152 (1995).
40. Gupta RK, Relyved ER, Lindblad EB et al. Adjuvants – a balance between toxicity and adjuvanticity. Vaccine 11 (4), 293 – 306 (1993).
41. Couette M, Boisse MF, Maison P et al. Long-term persistence of vaccine-derived aluminum hydroxide is associated with chronic cognitive dysfunction. J. Inorg. Biochem. 103 (11), 1571 – 1578 (2009).
42. Exley C, Siesjö P, Eriksson H. The immunobiology of aluminium adjuvants: how do they really work? Trends Immunol. 31 (3), 103 – 109 (2010).
43. Tomljenovic L, Shaw CA. Do aluminum vaccine adjuvants contribute to the rising prevalence of autism? J. Inorg. Biochem. 105 (11), 1489 – 1499 (2011).
44. Agmon-Levin N, Hughes GR, Shoenfeld Y. The spectrum of ASIA: 'Autoimmune (Auto-inflammatory) Syndrome induced by Adjuvants'. Lupus 21 (2), 118 – 120 (2012).
45. O'Hagan DT, Rappuoli R, De Gregorio E, Tsai T, Del Giudice G. MF59 adjuvant: the best insurance against influenza strain diversity. Expert Rev. Vaccines 10 (4), 447 – 462 (2011).
46. Banzhoff A, Pellegrini M, Del Giudice G, Fragapane E, Groth N, Podda A. MF59-adjuvanted vaccines for seasonal and pandemic influenza prophylaxis. Influenza Other Respir. Viruses 2 (6), 243 – 249 (2008).
47. O'Hagan DT, Ott GS, De Gregorio E, Seubert A. The mechanism of action of MF59 – an innately attractive adjuvant formulation. Vaccine 30 (29), 4341 – 4348 (2012).
48. El Sahly H. MF59; as a vaccine adjuvant: a review of safety and immunogenicity. Expert Rev. Vaccines 9 (10), 1135 – 1141 (2010).
49. Mannino S, Villa M, Apolone G et al. Effectiveness of adjuvanted influenza vaccination in elderly subjects in northern Italy. Am. J. Epidemiol. 176 (6), 527 – 533 (2012).
50. Vesikari T, Knuf M, Wutzler P et al. Oil-in-water emulsion adjuvant with influenza vaccine in young children. N. Engl. J. Med. 365, 1406 – 1416 (2011).
51. O’Hagan DT. MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection. Expert. Rev. Vaccines 6 (5), 699 – 710 (2007).
52. Roman F, Vaman T, Gerlach B, Markendorf A, Gillard P, Devaster JM. Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03A-adjuvant: Preliminary report of an observer-blind, randomised trial. Vaccine 28 (7), 1740 – 1745 (2010).
53. Atmar RL, Keitel WA. Adjuvants for pandemic influenza vaccines. Curr. Top. Microbiol. Immunol. 333, 323 – 344 (2009).
54. Gilca R, Deceuninck G, De Serres G et al. Effectiveness of pandemic H1N1 vaccine against influenza-related hospitalization in children. Pediatrics 128 (5), e 1084 – e1091 (2011).
55. McElhaney JE, Beran J, Devaster JM et al. AS03-adjuvanted versus non-adjuvanted inactivated trivalent influenza vaccine against seasonal influenza in elderly people: a phase 3 randomised trial. Lancet Infect. Dis. 13 (6), 485 – 496 (2013).
56. Eurosurveillance editorial team. Swedish Medical Products Agency publishes report from a case inventory study on Pandemrix vaccination and development of narcolepsy with cataplexy. Euro. Surveill. 16 (26) (2011).
57. Partinen M, Saarenpää-Heikkilä O, Ilveskoski I et al. Increased incidence and clinical picture of childhood narcolepsy following the 2009 H1N1 pandemic vaccination campaign in Finland. PLoS. One. 7 (3), e33723 (2012).
58. Bardage C, Persson I, Ortqvist A, Bergman U, Ludvigsson JF, Granath F. Neurological and autoimmune disorders after vaccination against pandemic influenza A (H1N1) with a monovalent adjuvanted vaccine: population based cohort study in Stockholm, Sweden. BMJ 343:d5956 (2011).
59. Isai A, Durand J, Le Meur S, Hidalgo-Simon A, Kurz X. Autoimmune disorders after immunization with Influenza A/H1N1 vaccines with and without adjuvant: EudraVigilance data and literature review. Vaccine 30(49) 7123 – 7129 (2012).
60. Herzog C, Hartmann K, Kunzi V et al. Eleven years of Inflexal® V – a virosomal adjuvanted influenza vaccine. Vaccine 27 (33), 4381 – 4387 (2009).
61. Mischler R, Metcalfe IC. Inflexal V a trivalent virosome subunit influenza vaccine: production. Vaccine 20 (Suppl. 5), B17 – B23 (2002).
62. Glück R, Mischler R, Finkel B, Que JU, Scarpa B, Cryz SJ Jr. Immunogenicity of new virosome influenza vaccine in elderly people. Lancet 344 (8916), 160 – 163 (1994).
63. Moser C, Amacker M, Kammer AR, Rasi S, Westerfeld N, Zurbriggen R. Influenza virosomes as a combined vaccine carrier and adjuvant system for prophylactic and therapeutic immunizations. Expert Rev. Vaccines 6 (5), 711 – 721 (2007).
64. Cusi MG. Applications of influenza virosomes as a delivery system. Hum. Vaccines J. 2 (1), 1 – 7 (2006).
65. Bungener L, Serre K, Bijl L et al. Virosome-mediated delivery of protein antigens to dendritic cells. Vaccine 20 (17–18), 2287 – 2295 (2002).
66. de Bruijn IA, Nauta J, Gerez L, Palache AM. The virosomal influenza vaccine Invivac: immunogenicity and tolerability compared to an adjuvanted influenza vaccine (Fluad in elderly subjects). Vaccine 24 (44 – 46), 6629 – 6631 (2006).
67. Johansen K, Nicoll A, Ciancio B C, Kramarz P. Pandemic influenza A(H1N1) 2009 vaccines in the European Union. Euro Surveill. 14 (41), 19361 (2009).
68. Vajo Z, Tamas F, Sinka L, Jankovics I. Safety and immunogenicity of a 2009 pandemic influenza A H1N1 vaccine when administered alone or simultaneously with the seasonal influenza vaccine for the 2009-10 influenza season: a multicentre, randomised controlled trial. Lancet 375 (9708), 49 – 55 (2010).
69. Riedl K, Riedl R, von Gabain A, Nagy E, Lingnau K. The novel adjuvant IC31 strongly improves influenza vaccine-specific cellular and humoral immune responses in young adult and aged mice. Vaccine 26 (27 – 28), 3461 – 3468 (2008).
70. Szabo A, Gogolak P, Pazmandi K et al. The two-component adjuvant IC31® boosts type i interferon production of human monocyte-derived dendritic cells via ligation of endosomal TLRs. PLoS One 8 (2), e55264 (2013).
71. Barber GN. Cytoplasmic DNA innate immune pathways. Immunol. Rev. 243 (1), 99 – 108 (2011).
72. Dynavax Technologies Corporation. A universal influenza vaccine using an M2e/NP fusion protein linked to immunostimulatory sequences. Presented at: The Vaccine 2nd Global Congress. Boston, MA, USA, 7 – 9 (2008).
73. Jasani B, Navabi H, Adams M. Ampligen: a potential toll-like 3 receptor adjuvant for immunotherapy of cancer. Vaccine 27 (25 – 26), 3401 – 3404 (2009).
74. Hayashi F, Smith K, Ozinsky A et al. The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. Nature 410 (6832), 1099 – 1103 (2001).
75. Huleatta JW, Nakaara V, Desaia P et al. Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin. Vaccine 26 (2), 201 – 214 (2008).
76. Turley CB, Rupp RE, Johnson C et al. Safety and immunogenicity of a recombinant M2e-flagellin influenza vaccine (STF2.4xM2e) in healthy adults. Vaccine 29 (32), 5145 – 5152 (2011).
77. Yedidia TB, Arnon R. Flagella as a platform for epitope-based vaccines. Isr. Med. Assoc. J. 8 (5), 316 – 318 (2006).
78. Atsmon J, Kate-Ilovitz E, Shaikevich D et al. Safety and immunogenicity of multimeric-001 – a novel universal influenza vaccine. J. Clin. Immunol. 32 (3), 595 – 603 (2012).
79. Peeka LJ, Middaugh CR, Berkland C. Nanotechnology in vaccine delivery. Adv. Drug. Deliv. Rev. 60 (8), 915 – 928 (2008).
80. Guebre-Xabier M, Hammond SA, Epperson DE, Yu J, Ellingsworth L, Glenn GM. Immunostimulant patch containing heat-labile enterotoxin from Escherichia coli enhances immune responses to injected influenza virus vaccine through activation of skin dendritic cells. J. Virol. 77 (9), 5218 – 5225 (2003).
81. Glenn GM, Thomas DN, Poffenberger KL et al. Safety and immunogenicity of an influenza vaccine A/H5N1 (A/Vietnam/1194/2004) when coadministered with a heat-labile enterotoxin (LT) adjuvant patch. Vaccine 27 (Suppl. 6), G 60 – G66 (2009).
82. Langley JM, Aoki F, Ward BJ et al. A nasally administered trivalent inactivated influenza vaccine is well tolerated, stimulates both mucosal and systemic immunity, and potentially protects against influenza illness. Vaccine 29 (10), 1921 – 1928 (2011).
83. Wei CJ, Boyington JC, McTamney PM et al. Induction of broadly neutralizing H1N1 influenza antibodies by vaccination. Science 329 (5995), 1060 – 1064 (2010).
84. Hubby B, Talarico T, Maughan M et al. Development and preclinical evaluation of an alphavirus replicon vaccine for influenza. Vaccine 25 (48), 8180 – 8189 (2007).
85. Van Kampen KR, Shi Z et al. Safety and immunogenicity of adenovirus-vectored nasal and epicutaneous influenza vaccines in humans. Vaccine 23 (8), 1029 – 1036 (2005).
86. Hem SL, Hogenesch H. Relationship between physical and chemical properties of aluminum-containing adjuvants and immunopotentiation. Expert Rev. Vaccines 6 (5), 685 – 698 (2007).
87. Tomljenovic L, Shaw CA. Mechanisms of aluminum adjuvant toxicity and autoimmunity in pediatric populations. Lupus 21 (2), 223 – 230 (2012).
88. Kool M, Fierens K, Lambrecht BN. Alum adjuvant: some of the tricks of the oldest adjuvant. J. Med. Microbiol. 61 (Pt 7): 927 – 934 (2012).
89. Sänger R, Schussmann KM, Preusche A et al. Immunogenicity and persistence of response to an alum-adjuvanted monovalent (H9N2) whole virus influenza vaccine in healthy adults aged 60 years and older. Presented at: International Conference on Influenza Vaccines for the World – IVW2006. Vienna, Austria, pp. 18 – 20 (2006).
90. Velasquez LS, Shira S, Berta AN. Intranasal delivery of Norwalk virus-like particles formulated in an in situ gelling, dry powder vaccine. Vaccine 29 (32): 5221 – 5231 (2011).
91. Ni Y, Tian L, Medi B, et al. Presented at: International Conference on Influenza Vaccines for the World – IVW2006. Vienna, Austria, pp. 18 – 20 (2006).
92. Wegmann F, Gartlan KH, Harandi AM et al. Polyethyleneimine is a potent mucosal adjuvant for viral glycoprotein antigens. Nat. Biotechnol. 30 (9), 883 – 888 (2012).
93. Landry N, Ward BJ, Trépanier S et al. Preclinical and clinical development of plant-made virus-like particle vaccine against avian H5N1 influenza. PLoS One 5 (12), e15559 (2010).
94. López-Macías C, Ferat-Osorio E, Tenorio-Calvo A et al. Safety and immunogenicity of a virus-like particle pandemic influenza A (H1N1) 2009 vaccine in a blinded, randomized, placebo controlled trial of adults in Mexico. Vaccine 29 (44), 7826 – 7834 (2011).
95. Khurana S, Wu J, Verma N et al. H5N1 virus-like particle vaccine elicitis cross-reactive neutralizing antibodies that preferentially bind to the oligomeric form of Influenza virus hemagglutinin in humans. J. Virol. 85 (21), 10945 – 10954 (2011).
96. Kang SM, Pushko P, Bright RA, Smith G, Compans RW. Influenza virus-like particles as pandemic vaccines. Curr. Top. Microbiol. Immunol. 333, 269 – 289 (2009).
97. Pushko P, Pearce MB, Ahmad A et al. Influenza virus-like particle can accommodate multiple subtypes of hemagglutinin and protect from multiple influenza types and subtypes. Vaccine 29 (35), 5911 – 5918 (2011).
98. Henriksen-Lacey M, Korsholm KS, Andersen P, Perrie Y, Christensen D. Liposomal vaccine delivery systems. Expert Opin. Drug Deliv. 8 (4), 505 – 519 (2011).
99. Samad A, Sultana Y, Aqil M. Liposomal drug delivery systems: an update review. Curr Drug Deliv. 4 (4), 297 – 305 (2007).
100. Liang MT, Davies NM, Blanchfield JT, Toth I. Particulate systems as adjuvants and carriers for peptide and protein antigens. Curr. Drug Deliv. 3 (4), 379 – 388 (2006).
101. Laing P, Bacon A, McCormack B, Gregoriadis G, Frisch B, Schuber F. The ‘co-delivery’ approach to liposomal vaccines: application to the development of influenza-A and hepatitis-B vaccine candidates. J. Liposome Res. 16 (3), 229 – 235 (2006).
102. Xiong F, Mi Z, Gu N. Cationic liposomes as gene delivery system: transfection efficiency and new application. Pharmazie 66 (3), 158 – 164 (2011).
103. Dalkara D, Chandrashekhar C, Zuber G. Intracellular protein delivery with a dimerizable amphiphile for improved complex stability and prolonged protein release in the cytoplasm of adherent cell lines. J. Control. Release 116 (3), 353 – 359 (2006).
104. Kang SH, Cho HJ, Shim G et al. Cationic liposomal co-delivery of small Interfering RNA and a MEK inhibitor for enhanced anticancer efficacy. Pharm. Res. 28 (12), 3069 – 3078 (2011).
105. Shegokar R, Al Shaal L, Mishra PR. SiRNA delivery: challenges and role of carrier systems. Pharmazie 66 (5), 313 – 318 (2011).
106. Mutsaers SE, Papadimitriou JM. Surface charge of macrophages and their interaction with charged particles. J. Leukocyte Biol. 44 (1), 17 – 26 (1988).
107. Kawakami S, Hattori Y, Lu Y, Higuchi Y, Yamashita F, Hashida M. Effect of cationic charge on receptor-mediated transfection using mannosylated cationic liposome/plasmid DNA complexes following the intravenous administration in mice. Pharmazie 59 (5), 405 – 408 (2004).
108. Foged C, Arigita C, Sundblad A, Jiskoot W, Storm G, Frokjaer S. Interaction of dendritic cells with antigen-containing liposomes: effect of bilayer composition. Vaccine 22(15 – 16), 1903 – 1913 (2004).
109. Henriksen-Lacey M, Bramwell VW, Christensen D, Agger EM, Andersen P, Perrie Y. Liposomes based on dimethyldioctadecylammonium promote a depot effect and enhance immunogenicity of soluble antigen. J. Control. Release 142 (2), 180 – 186 (2010).
110. Korsholm KS, Agger EM, Foged C et al. The adjuvant mechanism of cationic dimethyldioctadecylammonium liposomes. Immunology 121 (2), 216 – 226 (2007).
111. Lonez C, Vandenbranden M, Ruysschaert JM. Cationic liposomal lipids: From gene carriers to cell signaling. Prog. Lipid Res. 47 (5), 340 – 347 (2008).
112. Zhou F, Huang L. Liposome-mediated cytoplasmic delivery of protein s: an effective means of accessing the MHC class I-restricted antigen presentation pathway. Immunomethods 4 (3), 229 – 235 (1994).
113. Joseph A, Itskovitz-Cooper N, Samira S et al. A new intranasal influenza vaccine based on a novel polycationic lipid-ceramide carbamoyl- spermine (CCS) I. Immunogenicity and efficacy studies in mice. Vaccine 24 (18), 3990 – 4006 (2006).
114. Babai I, Samira S, Barenholz Y, Zakay-Rones Z, Kedar E. A novel influenza subunit vaccine composed of liposome-encapsulated haemagglutinin/neuraminidase and IL-2 or GM-CSF. I. Vaccine characterization and efficacy studies in mice. Vaccine 17 (9 – 10), 1223 – 1238 (1999).
115. I., Babai, S., Samira, Y., Barenholz, Z., Zakay-Rones, E., Kedar, A novel influenza subunit vaccine composed of liposome-encapsulated haemagglutinin/neuraminidase and IL-2 or GM-CSF. II. Induction of TH1 and TH2 responses in mice, Vaccine, (1999), 17, 9, 10, 1239-1250
116. Joseph A, Louria-Hayon I, Plis-Finarov A et al. Liposomal immunostimulatory DNA sequences (ISS-ODN): an efficient parenteral and mucosal adjuvant for influenza and hepatitis B vaccines. Vaccine 20 (27 – 28), 3342 – 3354 (2002).
117. Even-Or O, Joseph A, Itskovitz-Cooper N et al. A new intranasal influenza vaccine based on a novel polycationic lipid – ceramide carbamoyl-spermine (CCS). II. Studies in mice and ferrets and mechanism of adjuvanticity. Vaccine 29 (13), 2474 – 2486 (2011).
118. Even-Or O, Samira S, Rochlin E et al. Immunogenicity, protective efficacy and mechanism of novel CCS adjuvanted influenza vaccine. Vaccine 28 (39), 6527 – 6541 (2010).
119. Ben-Yehuda A, Joseph A, Zeira E et al. Immunogenicity and safety of a novel liposomal influenza subunit vaccine (INFLUSOME-VAC) in young adults. J. Med. Virol. 69 (4): 560 – 567 (2003).
120. Ben-Yehuda A, Joseph A, Barenholz Y et al. Immunogenicity and safety of a novel IL-2-supplemented liposomal influenza vaccine (INFLUSOME-VAC) in nursing-home residents. Vaccine 21 (23), 3169 – 3178 (2003).
121. Agger EM, Rosenkrands I, Hansen J et al. Cationic liposomes formulated with synthetic mycobacterial cordfactor (CAF01): a versatile adjuvant for vaccines with different immunological requirements. PloS One 3 (9), e3116 (2008).
122. Rosenkrands I, Vingsbo-Lundberg C et al. Enhanced humoral and cell-mediated immune responses after immunization with trivalent influenza vaccine adjuvanted with cationic liposomes. Vaccine 29 (37), 6283 – 6291 (2011).
123. Heikenwalder M, Polymenidou M, Junt T et al. Lymphoid follicle destruction and immunosuppression after repeated CpG oligodeoxynucleotide administration. Nat. Med. 10 (2), 187 – 192 (2004).
124. Novartis receives FDA approval for Flucelvax®, the first cell-culture vaccine in US to help protect against seasonal influenza (2012). www.novartis.com/newsroom/media-releases/en/2012/1659272.shtml
125. Baxter receives approval for Preflucel seasonal influenza vaccine in Austria (2010). www.baxter.com/press_room/press_releases/2010/09_29_10_preflucel.html
126. Sanofi Pasteur presents new data confirming Fluzone® High-Dose (influenza virus vaccine) produces higher antibody response in the age 65+ population (2011). sanofipasteurus.mediaroom.com/index.php?s=11069&item=73142
127. Influenza Vaccine May Reduce Risk of Heart Disease and Death: Flu Shot May Reduce Risk of Major Cardiac Event by 50 Percent (2012). www.sciencedaily.com/releases/2012/10/121028141719.htm
128. The Compelling Need for Game-Changing Influenza Vaccines: An Analysis of the Influenza Vaccine Enterprise and Recommendations for the Future (2012). www.cidrap.umn.edu/cidrap/files/80/ccivi%20report.pdf
129. All three Novartis A(H1N1) 2009 influenza vaccines prequalified by World Health Organization (WHO) for use in developing world (2009). www.novartis.com/newsroom/media-releases/en/2009/1365351.shtml
130. ‘Pandemrix packaging information’. www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000832/WC500038121.pdf
131. Narcolepsy in association with pandemic influenza vaccination – a multi-country European epidemiological investigation (2012). www.ecdc.europa.eu/en/publications/Publications/Forms/ECDC_DispForm.aspx?ID=959
132. French study finds narcolepsy link to H1N1 vaccine in adults (2012). www.cidrap.umn.edu/cidrap/content/influenza/swineflu/news/sep2112narcolepsy.html
133. European Medicines Agency reviews hypothesis on Pandemrix and development of narcolepsy (2012). www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2012/10/news_detail_001636.jsp&mid=WC0b01ac058004d5c1.
134. ADJUVANT IC31® (2012). www.intercell.com/main/forvaccperts/technologies/adjuvant-ic31r/
135. Dynavax Technologies. www.dynavax.com
136. Hemispherx Biopharma Announces Test of Ampligen® with FluMist (2012). www.hemispherx.net/content/investor/default.asp?goto=732
137. Immediate Report of BiondVax Pharmaceuticals Ltd., filed with the Israeli Securities Authority (2007). maya.tase.co.il/bursa/report.asp?report_cd=289007
138. Successful Phase I/II clinical trial for BiondVax Pharmaceuticals' universal flu vaccine. (2009). www.medicalnewstoday.com/articles/173210.php
139. The Multimeric Universal Influenza Vaccine: BVX-M001 (2012). www.biondvax.com/128084/Product
140. BiondVax announces positive Phase IIa results for universal flu vaccine (2011). www.biondvax.com/image/users/128084/ftp/my_files/Press%20Releases/BiondVax%20-%2016%20June%202011%20-%20Phase%20IIa%20Results.pdf?id=8536118
141. BiondVax reports success in 4th universal flu vaccine trial (2012). www.globes.co.il/serveen/globes/docview.asp?did=1000725443&fid=1725
142. Intercell announces Phase I results on its Vaccine Enhancement Patch (VEP) with Pandemic Influenza antigens (2012). www.intercell.com/main/company/news/news-full/article/intercell-announces-phase-i-results-on-its-vaccine-enhancement-patch-vep-with-pandemic-influenza-a/
143. Mucosis announces positive proof-of-concept data for Mimopath® platform in humans (2012). www.mucosis.com/press_releases_10-05-12.php
144. ALPHAVAX ANNOUNCES RESULTS FROM PHASE 1 INFLUENZA VACCINE CLINICAL TRIAL www.alphavax.com/docs/pr/release_43.pdf
145. Alphavax. www.alphavax.com
146. Vaxin. www.vaxin.com
147. Nanobio, www.nanobio.com
148. Nanobio passes first key clinical trial with nasal flu vaccine, scopes other opportunities (2010). www.ventureinvestors.com/archives/2400
149. Nasvax. www.nasvax.com